Differential effects of ibogaine pretreatment on brain levels of morphine and (+)-amphetamine.
S D Glick, C A Gallagher, L B Hough, K L Rossman, I M Maisonneuve
Brain research August 14, 1992 DOI: 10.1016/0006-8993(92)91360-q via PubMed
Summary
AI-generated from the abstractIbogaine pretreatment in rats did not alter brain morphine levels at 30 minutes or 2 hours after injection, but it significantly increased brain amphetamine levels at both time points, with a greater increase at 2 hours. These findings suggest that ibogaine irreversibly inhibits an enzyme that metabolizes amphetamine, indicating that the functional interactions between ibogaine and amphetamine, unlike those with morphine, may stem from a drug-drug interaction in the liver.
Study at a glance
| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Intervention | Ibogaine pretreatment |
| Duration | 19 h pretreatment, measurements at 30 min and 2 h after injection |
| Citations | 21 |
| Key finding | Ibogaine pretreatment increased brain amphetamine levels but had no effect on brain morphine levels, suggesting a hepatic drug-drug interaction underlies ibogaine's interaction with amphetamine but not with morphine. |
Abstract
Previous studies in rats have shown that ibogaine inhibits neurochemical and behavioral effects of morphine yet potentiates similar effects of (+)-amphetamine. To assess whether these different functional interactions have a metabolic basis, brain levels of morphine and (+)-amphetamine were measured by gas chromatography-mass spectrometry after ibogaine pretreatment (19 h before injection of morphine or (+)-amphetamine). Ibogaine pretreatment had no effect on brain morphine levels, either at 30 min or 2 h after morphine injection; however, ibogaine significantly increased brain amphetamine levels at 30 min and, to a greater extent, at 2 h after (+)-amphetamine injection. These and other data suggest that ibogaine irreversibly inhibits an amphetamine-metabolizing enzyme. The functional interactions between ibogaine and (+)-amphetamine, but not those between ibogaine and morphine, may result from a hepatic drug-drug interaction.